2025.03.31

XIwen | Qingpu District Economic Commission and park leaders visited Constream Biotechlogical for guidance

To gain a deeper understanding of the development needs of enterprises, provide precise services for enterprise innovation and growth, and promote the high-quality development of Qingpu District's biopharmaceutical industry, on March 31, 2025, Li Yujie, Deputy Director of the Qingpu District Economic Committee, led a team, together with relevant personnel from Qingpu Industrial Park, Qingfa Group, Songyuan Fund, and Zhangjiang Yunlifang, to visit and investigate Shanghai Constream Biotechtechnology Co., Ltd. (hereinafter referred to as "Constream Biotech"), conducting on-site inspections of the company's research and development achievements and operating conditions, and holding discussions on policy support, industrial collaboration, and capital docking.

2025.02.26

Xiwen | Constream Biotech participation in the 6th ADC Drug Development Conference 2025 concludes successfully

The 6th ADC Drug Development Conference 2025, held on February 20th and 21st, was successfully concluded to great anticipation. Meticulously organized by the host, the conference attracted numerous industry experts, corporate representatives, and researchers. The event brought together cutting-edge perspectives and innovative technologies, creating a vibrant atmosphere over the two days and providing a high-quality platform for communication and collaboration in the ADC drug development field.

2025.01.17

Xi News | The Constream Biotech Flows Long and Steady, Aiming Far - Annual Meeting Special

As the year turns and a new chapter unfolds, Shanghai Constream Biotech's New Year's party was grandly held amidst much anticipation, under the beautiful aspiration of "The stream flows long, steady and far". This is not only a heartfelt review of the past year, but also a warm moment for all Constream Biotech people to gather together and look forward to the future.

2025.01.03

Xiwen | Alumni company Constream Biotech participated in the 9th Fudan University Biomedicine Academic Exchange Conference

With the booming development of biomedical innovation, various academic exchange activities have become a stage for industry thought collision, technology display, and cooperation expansion.

2024.10.22

Xiwen | Team Building Trip by Dianshan Lake

In today's fast-paced work environment, we are always searching for opportunities to relax and strengthen team bonds. On October 18th, Shanghai Constream Biotech, under the banner of "United Hearts, Shared Success," led a group of passionate and ambitious colleagues on a team-building trip to Dianshan Lake, creating unforgettable memories!

2025.03.27

Seizing the Opportunity: SOX17, the Next PD-1?

The immune system is the body's core defense against tumors, but cancer cells often camouflage themselves through "immune escape" mechanisms to avoid detection and attack by immune cells. Currently, immune checkpoint therapy, represented by PD-1/PD-L1 inhibitors, has achieved breakthroughs in advanced cancers, but its effectiveness is limited in early-stage tumors (such as colorectal cancer).

2025.01.09

Xi News | Synthetic Fab HuCAL GOLD library screening helps Fizeto monoclonal antibody to market

On January 8, 2025, Tianjing Bio's application for the marketing of its CD38 antibody injection, Fizetomab, was accepted by the NMPA. This milestone is undoubtedly a new ray of hope for the second-line treatment of multiple myeloma patients.

2025.01.05

Xi News | Antibodies to Watch in 2025: 11 domestically developed antibody products have applied for listing

The commercial development of antibody therapeutics is a global endeavor involving tens of thousands of biopharmaceutical companies and supporting service organizations. Their combined efforts have resulted in over 200 antibody therapeutics on the market to date, with nearly 1400 more product candidates in various stages of clinical trials for a wide range of diseases.

2025.01.02

Xi News | A fully human Fab phage display library accelerates the screening of antibody molecules targeting STEAP1

STEAP1 belongs to the prostate transmembrane epithelial antigen (STEAP) family, which, besides STEAP1, includes STEAP2, STEAP3, and STEAP4. These proteins are involved in numerous biological processes, including apoptosis and proliferation, oxidative stress, and intracellular and extracellular molecular transport.